DT03 Rec'd PCT/PTO 0 7 OCT 2004

ATTORNEY'S DOCKET NUMBER FORM PTO-1390 (Modified) (PEV. 07-2004) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE **PU4725USW** TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/US03/10747 4/8/03 4/8/02 TITLE OF INVENTION CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR APPLICANT(S) FOR DO/EO/US Neil Lee SPECTOR and Wenle XIA Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2 This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), 3. (6), (9) and (24) indicated below. \boxtimes The US has been elected (Article 31). 4 5. A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) is attached hereto (required only if not communicated by the International Bureau). a. 🗆 b. 🗆 has been communicated by the International Bureau. c. 🛛 is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗆 is attached hereto. b. 🗆 has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. 🗆 have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. \boxtimes An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11 Ø A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. \boxtimes A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: \boxtimes An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. \bowtie 15. A FIRST preliminary amendment. 16. A SECOND or SUBSEQUENT preliminary amendment. 17. A substitute specification. 18. A power of attorney and/or change of address letter. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 21. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 22. X Express Mail Label No. EV330919603US 23. Other items or information: **PCT Publication Coverpage** PCT Notification of the Recording of a Change

DT18 Rec'd POT/PTO 0 7 INTERNATIONAL APPLICATION NO. U.S. APPLICATION NO (if known, see 37 CFR 1.5). PCT/US03/10747 PU4725USW 24. The following fees are submitted:. CALCULATIONS PTO USE ONLY BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1080.00 and International Search Report not prepared by the EPO or JPO International preliminary examination fee (37 CFR 1.482) not paid to \$920.00 USPTO but International Search Report prepared by the EPO or JPO International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$770.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$730.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4).... \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$920.00 Surcharge of \$130.00 for furnishing the oath or declaration later than \$0.00 months from the earliest claimed priority date (37 CFR 1.492(e)). NUMBER EXTRA **RATE CLAIMS NUMBER FILED** \$18.00 \$0.00 20 - 20 = Total claims \$946.00 11 \$86.00 14 - 3 = Independent claims \$0.00 Multiple Dependent Claims (check if applicable) TOTAL OF ABOVE CALCULATIONS \$1,866.00 Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are \$0.00 reduced by 1/2. **SUBTOTAL** \$1,866.00 □ 20 □ 30 Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). \$0.00 TOTAL NATIONAL FEE \$1,866.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). \$0.00 TOTAL FEES ENCLOSED \$1,866.00 Amount to be: refunded \$ charged to cover the above fees is enclosed. A check in the amount of Please charge my Deposit Account No. 07-1392 in the amount of \$1,866.00 to cover the above fees. X b. \boxtimes The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment c. to Deposit Account No. 07-1392 Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card d. information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: John L. Lemanowicz **Customer Number** 23347 37,380 REGISTRATION NUMBER

		· DIOS RECUPCIÓN	U U / UCI 2004
CERTIFICATE OF Applicant(s): Spector et		MAIL" (37 CFR	10 / Pole 0 5 4 2 PU4725USW
Serial No. To Be Assigned	Filing Date	Examiner	Group Art Unit
Invention: CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR			
I hereby certify that the following correspondence: Transmittal Letter to the DO/EO/US Concerning a Filing Under 37 U.S.C. 371			
Translittal Letter to the DO/EO/O3 Concerning a Fining Order 37 C.S.C. 371			
(Identify type of correspondence)			
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37			
CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on			
10/7/04 (Para)			
(Date)			
Allyson K. Jacobs (Typed or Printed Name of Person Mailing Correspondence)			
Alluson K. Jacobs			
(Signature of Person Mailing Correspondence)			
ZUEDAPLPOEEV3 (Substitution of the control of the c			
Nets. Each warm would have its own contificate of mailing			
Note: Each paper must have its own certificate of mailing.			